Related Experiment Video
Updated: Mar 4, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
Role of Gut Microbiota in Immune Checkpoint Inhibitor Therapy
Yue-Chun Fu1, Bing Pang2, Shao-Bo Liang2
1Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
None:
Immune checkpoint inhibitors (ICIs), which have become the primary treatment of carcinomas in recent years, not only bring survival benefits to patients, but also come with various side effects. Studies have shown that different gut microbiota groups have different effects on the efficacy and side effects of ICIs. Here, we summarize the relevant research progress on gut microbiota and the efficacy and side effects of ICIs, explore the mechanisms of the gut microbiota in modulating anticancer immunotherapy and further discuss treatment strategies of how the gut microbiota enhancing the efficacy and reducing side effects of ICIs. This study aims to identify specific gut microbiota as potential biomarkers for ICI treatment to screen for patients who may respond effectively to ICI treatment, thereby improving efficacy and mitigating side effects.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
The Tumor Microenvironment
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Microorganisms in Medicine and Therapeutics

